Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia

被引：48
作者：
Ulhaq, Zulvikar Syambani [1 ]
Soraya, Gita Vita [2 ]
机构：
[1] Maulana Malik Ibrahim Islamic State Univ Malang, Dept Biochem, Fac Med & Hlth Sci, Batu 65151, East Java, Indonesia
[2] Hasanuddin Univ, Dept Biochem, Fac Med, Makassar 90245, South Sulawesi, Indonesia
来源：
MEDICINA CLINICA | 2020年 / 155卷 / 12期
关键词：
OFF-LABEL USE; TOCILIZUMAB; INTERLEUKIN-6;
D O I：
10.1016/j.medcli.2020.07.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：548 / 556
页数：9
相关论文
共 50 条
  • [31] Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies
    Zhao, Ming
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (06)
  • [32] The role of IL-6/lymphocyte ratio in the peripheral blood of severe patients with COVID-19
    Yang, Boyi
    Chang, Xiaoyan
    Huang, Jiabao
    Pan, Wen
    Si, Zhilong
    Zhang, Cuntai
    Li, Hong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 97 : 107569
  • [33] A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients
    Solis-Garcia Del Pozo, J.
    Galindo, M. F.
    Nava, E.
    Jordan, J.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (13) : 7475 - 7484
  • [34] IL-6 and other biomarkers as predictors of severity in COVID-19
    Broman, N.
    Rantasarkka, K.
    Feuth, T.
    Valtonen, M.
    Waris, M.
    Hohenthal, U.
    Rintala, E.
    Karlsson, A.
    Marttila, H.
    Peltola, V.
    Vuorinen, T.
    Oksi, J.
    ANNALS OF MEDICINE, 2021, 53 (01) : 410 - 412
  • [35] Could IL-6 predict the clinical severity of COVID-19?
    Aykal, Guzin
    Esen, Hatice
    Seyman, Derya
    Caliskan, Tugba
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2021, 46 (05): : 499 - 507
  • [36] New tale on LianHuaQingWen: IL6R/IL6/IL6ST complex is a potential target for COVID-19 treatment
    Zhao Tianyu
    Cui Xiaoli
    Wang Yaru
    Min, Zhang
    Yue Fengli
    Kan, He
    Li, Chen
    Jing, Li
    AGING-US, 2021, 13 (21): : 23913 - 23935
  • [37] Multimodality treatment in immunocompromised patients with severe COVID-19: the role of IL-6 inhibitor, intravenous immunoglobulin, and haemoperfusion
    Leelayuwatanakul, Nophol
    Kongpolprom, Napplika
    Sriprasart, Thitiwat
    Phoophiboon, Vorakamol
    Thanthitaweewat, Vorawut
    Thawanaphong, Sarita
    Sirichana, Worawan
    Chirakalwasan, Naricha
    Kawkitinarong, Kamon
    Sittipunt, Chanchai
    Putcharoen, Opass
    Paitoonpong, Leilani
    Suwanpimolkul, Gompol
    Jantarabenjakul, Watsamon
    Srisawat, Nattachai
    Pachinburavan, Monvasi
    RESPIROLOGY CASE REPORTS, 2021, 9 (04):
  • [38] Anti-IL6 treatment of serious COVID-19 disease A monocentric retrospective experience
    Castelnovo, Laura
    Tamburello, Antonio
    Lurati, Alfredo
    Zaccara, Eleonora
    Marrazza, Maria Grazia
    Olivetti, Micol
    Mumoli, Nicola
    Mastroiacovo, Daniela
    Colombo, Daniele
    Ricchiuti, Elisabetta
    Vigano', Paolo
    Paola, Faggioli
    Mazzone, Antonino
    MEDICINE, 2021, 100 (01) : E23582
  • [39] Anti-IL-6 receptor antibody improves pain symptoms in mice with experimental autoimmune encephalomyelitis
    Serizawa, Kenichi
    Tomizawa-Shinohara, Haruna
    Magi, Mayu
    Yogo, Kenji
    Matsumoto, Yoshihiro
    JOURNAL OF NEUROIMMUNOLOGY, 2018, 319 : 71 - 79
  • [40] Cytokine storm and translating IL-6 biology into effective treatments for COVID-19
    Li, Tiantian
    Wang, Dongsheng
    Wei, Haiming
    Xu, Xiaoling
    FRONTIERS OF MEDICINE, 2023, 17 (06) : 1080 - 1095
12345